



Daiichi Sankyo Sponsored Research

Guidelines for Application

Eligibility: Researchers affiliated with universities and research institutions, who have ideas which may lead to drug discovery. The program is not open to undergraduate or graduate students.

Research Budget: up to \$230,000 for one year including overhead/indirect costs

Term: 1-3 years. Successful program(s) will be considered for staging into collaborative research.

Selection Criteria:

- Matching needs (Research interests)
- Originality and uniqueness of research
- Drug discovery potential
- Feasibility of research plan
- Non-redundancy with Daiichi Sankyo's internal research projects and current collaboration

Deadline: Rolling application (until March 2024)

Research Interests

Oncology

- I. Novel targeted protein degradation technology other than ubiquitin-proteasome system (ex. autophagy-lysosome pathway)
- II. Novel IO targets focused on pml-derived MDSCs, ILCs or enhancement of tumor antigenicity (for which mechanisms are confirmed in human-derived samples)
- III. In vitro assay system that reflects in vivo epigenetic status and mechanism analysis of epigenetics targeting small molecule compounds
- IV. Novel hit / lead finding technology targeting “undruggable” proteins especially in the epigenetics area

Non-Oncology

- I. Novel disease relevant target identification research by using patient tissue samples or genetical analysis for the following target diseases (* both are neuroinflammation perspective)
 - a) Immune diseases: refractory immune diseases and lung fibrosis
 - b) Neurodegenerative diseases*: Alzheimer’s disease, Parkinson’s disease and ALS
 - c) Psychiatric diseases*: Schizophrenia, Autism spectrum disorder, addiction & anxiety, major depression disorders
 - d) Rare diseases: CNS, liver (mono or double genetic)



Daiichi-Sankyo

- e) Ophthalmological disorders (AMD, RP and PDR)
- II. Novel in vitro (iPSC derived) and in vivo models that recapture human pathological mechanisms/conditions of immune and psychiatric diseases described above
- III. Biomarker research for patient stratification in neuroinflammation derived disease described above
- IV. Drug delivery technologies for siRNAs to brain, heart, lung & kidney
- V. Novel RNA targeting small molecules & editing technologies (not RNase2, Ago2 & ADAR) with CNS diseases and rare diseases target
- VI. AAV platform: new capsid library (CNS target)

Parallel Application to Other non-Daiichi Sankyo Grants

Public Grant

DS may accept an application for a research topic by an individual that has already applied for a public grant for such research topic so long as the applicable intellectual property is controlled by either the PI and/or university.

Pharma-Sponsored Grant

DS may accept an application for a research topic by an individual that has already applied for a private grant for such research topic, but DS reserves the right to decline such application for any reason, including if such individual accepts a private grant.